KW-2478

TargetMol
Product Code: TAR-T6558
Supplier: TargetMol
CodeSizePrice
TAR-T6558-1mg1mg£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6558-2mg2mg£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6558-5mg5mg£206.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6558-1mL1 mL * 10 mM (in DMSO)£244.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6558-10mg10mg£267.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6558-25mg25mg£436.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6558-50mg50mg£598.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6558-100mg100mg£784.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
KW-2478 is a non-ansamycin HSP90 inhibitor with IC50 of 3.8 nM.
CAS:
819812-04-9
Formula:
C30H42N2O9
Molecular Weight:
574.671
Pathway:
Metabolism; Cytoskeletal Signaling
Purity:
0.9875
SMILES:
CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC
Target:
HSP

References

Takayuki Nakashima, et al. Clin Cancer Res, 2010, 16(10), 2792-2802. Ishii T, et al. Blood Cancer J, 2012, 2(4), e68. Juliger S, et al. ASH Annual Meeting and Exposition, 2008. Li H J, Wang Q S, Han W, et al. Anti-NSCLC activity in vitro of Hsp90N inhibitor KW-2478 and complex crystal structure determination of Hsp90N-KW-2478. Journal of Structural Biology. 2021, 213(2): 107710. Zeng D, Gao M, Zheng R, et al. The HSP90 inhibitor KW-2478 depletes the?malignancy of?BCR/ABL and?overcomes the?imatinib-resistance caused by?BCR/ABL amplifcation. Experimental Hematology & Oncology. 2022, 11(1): 1-14 Zeng D, Gao M, Zheng R, et al. The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification. Experimental Hematology & Oncology. 2022, 11(1): 1-14